$237 Million is the total value of Affinity Asset Advisors, LLC's 54 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BPMC | Exit | BLUEPRINT MEDICINES CORP | $0 | – | -1,988 | -100.0% | -0.02% | – |
| Exit | HYPERFINE INC | $0 | – | -76,162 | -100.0% | -0.04% | – | |
| CALA | Exit | CALITHERA BIOSCIENCES INC | $0 | – | -1,000,000 | -100.0% | -0.06% | – |
| CNTA | Exit | CENTESSA PHARMACEUTICALS PLCsponsored ads | $0 | – | -65,282 | -100.0% | -0.09% | – |
| ATHX | Exit | ATHERSYS INC NEWput | $0 | – | -1,416,400 | -100.0% | -0.14% | – |
| CYCC | Exit | CYCLACEL PHARMACEUTICALS INC | $0 | – | -400,000 | -100.0% | -0.20% | – |
| BEAM | Exit | BEAM THERAPEUTICS INCcall | $0 | – | -30,000 | -100.0% | -0.28% | – |
| AUPH | Exit | AURINIA PHARMACEUTICALS INCcall | $0 | – | -175,000 | -100.0% | -0.35% | – |
| RLAY | Exit | RELAY THERAPEUTICS INCcall | $0 | – | -75,000 | -100.0% | -0.36% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -70,000 | -100.0% | -0.39% | – |
| XENE | Exit | XENON PHARMACEUTICALS INC | $0 | – | -80,000 | -100.0% | -0.39% | – |
| CERE | Exit | CEREVEL THERAPEUTICS HLDNG I | $0 | – | -70,000 | -100.0% | -0.39% | – |
| TVTX | Exit | TRAVERE THERAPEUTICS INC | $0 | – | -100,000 | -100.0% | -0.41% | – |
| MSAC | Exit | MEDICUS SCIENCES ACQUISITION | $0 | – | -300,000 | -100.0% | -0.47% | – |
| HSAQ | Exit | HEALTH SCIENCES ACQ CORP 2 | $0 | – | -300,000 | -100.0% | -0.48% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INCput | $0 | – | -215,900 | -100.0% | -0.82% | – |
| NSTG | Exit | NANOSTRING TECHNOLOGIES INC | $0 | – | -171,592 | -100.0% | -0.95% | – |
| PMVP | Exit | PMV PHARMACEUTICALS INCcall | $0 | – | -317,400 | -100.0% | -1.06% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -300,000 | -100.0% | -1.14% | – |
| SWTX | Exit | SPRINGWORKS THERAPEUTICS INCput | $0 | – | -160,000 | -100.0% | -1.44% | – |
| SWTX | Exit | SPRINGWORKS THERAPEUTICS INC | $0 | – | -247,000 | -100.0% | -2.23% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -750,000 | -100.0% | -54.19% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MORPHIC HOLDING INC | 12 | Q3 2023 | 6.9% |
| KURA ONCOLOGY INC | 12 | Q3 2023 | 7.2% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 1.9% |
| IMMATICS N.V | 12 | Q3 2023 | 0.4% |
| CHINOOK THERAPEUTICS INC | 11 | Q2 2023 | 8.4% |
| ESTABLISHMENT LABS HLDGS INC | 11 | Q3 2023 | 8.3% |
| VINCERX PHARMA INC | 11 | Q2 2023 | 4.5% |
| ASCENDIS PHARMA A/S | 11 | Q3 2023 | 4.9% |
| CYTOKINETICS INC | 11 | Q3 2023 | 2.6% |
| INARI MED INC | 10 | Q1 2023 | 6.4% |
View Affinity Asset Advisors, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 03, 2023 | 7,477,000 | 9.2% |
View Affinity Asset Advisors, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-07 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-08-21 |
| 13F-HR | 2023-08-14 |
| SC 13G | 2023-07-03 |
| 13F-HR | 2023-05-15 |
View Affinity Asset Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.